Evaluating the Ability of Zoledronic Acid to Reduce the Rate of Subsequent Osteoporotic Fractures After a Hip Fracture
Evaluating the Ability of Zoledronic Acid to Reduce the Rate of Subsequent Osteoporotic Fractures After a Hip Fracture
The purpose of this study is to evaluate whether zoledronic acid given once yearly for two
 years to men and women after surgical repair of a recent hip fracture will significantly
 reduce the rate of all re-occurring (new) osteoporotic fractures. All patients will receive
 vitamin D and calcium.
Inclusion Criteria:

 -  Male or female ages 50 years or older

 -  Must have a recent hip fracture repair in the past 90 days

 -  Must be able to walk with or without assistive device (for example, using a walker)
 prior to the hip fracture

 Exclusion Criteria:

 -  Current bisphosphonate users such as aredia (pamidronate), didronel (etidronate),
 fosamax (alendronate), actonel (residronate), skelid (tiludronate)

 Other protocol-defined inclusion/exclusion criteria may apply.